-
FDA approves Novartis drug for rare blood disorder
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for removing excess iron from the blood in patients with a rare genetic disorder, the agency said.
The FDA announced the approval of Novartis' Exjade (deferasirox) for patients ages 10 years and older with chronic iron overload resulting from nontransfution-dependent thalassemia, or NTDT. A companion diagnostic, FerriScan, made by Australia-based Resonance Health, also was approved.
-
Parents not very concerned about prescription narcotic misuse, poll finds
ANN ARBOR, Mich. — A new study indicated that some parents may not be sufficiently concerned about misuse of narcotic painkillers by children and teenagers.